1.Subjects who are not able to or not willing to sign an IRB/IEC approved consent form or refusal to participate by legally authorized representative, if present. <br/ >2.Hospitalization or need for immediate medical attention in the clinical opinion of the study investigator. <br/ >3.Haemoglobin <10 g/dL in men and <9 g/dL in women. <br/ > <br/ >4.Platelet count <125,000/L. <br/ > <br/ >5.Estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73m2 <br/ > <br/ >6.Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevated over 5 times the ULN. <br/ >7.Patient is Pregnant or lactating women <br/ > <br/ >8.Recipient of SARS-CoV-2 vaccine. <br/ > <br/ >9.Known allergy/sensitivity or any hypersensitivity to components of test drug, or its formulation. <br/ > <br/ >10.Use of therapeutic interventions with possible anti-SARS-CoV-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, convalescent plasma, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. <br/ >11.Patients currently taking nucleos(t)ide analogues/ immunosuppressive treatments within 30 days of study enrolment or systemic corticosteroids. <br/ >12.Presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation. <br/ >13.Patients having chronic bronchitis and/or emphysema, psychiatric, musculoskeletal, or cardiovascular diseases. <br/ >14.Patients suffering from concurrent systemic diseases, with cardiopulmonary tuberculosis, pulmonary eosinophilia, bronchiectasis, cancer, congestive heart failure, hepatic dysfunction, and neurological disorders. <br/ >15.Patients with severe disease, defined as pneumonia plus one of the following: respiratory rate â?¥30 per minute, breathlessness, SpO2 â?¤ 92 on room air. <br/ >16.Use of systemic corticosteroid therapy (this may affect peripheral muscle function). <br/ >17.Subjects who are known cases of immune-compromised or autoimmune condition such as HIV, Hepatitis. <br/ >18.ICU Patient and having severe COVID19 symptoms, known chronic kidney disease stage 4 or 5 or receiving dialysis. <br/ >19.Inability to take or tolerate oral medications.

1.Subjects who are not able to or not willing to sign an IRB/IEC approved consent form or refusal to participate by legally authorized representative, if present. <br/ >2.Hospitalization or need for immediate medical attention in the clinical opinion of the study investigator. <br/ >3.Haemoglobin <10 g/dL in men and <9 g/dL in women. <br/ > <br/ >4.Platelet count <125,000/L. <br/ > <br/ >5.Estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73m2 <br/ > <br/ >6.Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevated over 5 times the ULN. <br/ >7.Patient is Pregnant or lactating women <br/ > <br/ >8.Recipient of SARS-CoV-2 vaccine. <br/ > <br/ >9.Known allergy/sensitivity or any hypersensitivity to components of test drug, or its formulation. <br/ > <br/ >10.Use of therapeutic interventions with possible anti-SARS-CoV-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, convalescent plasma, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. <br/ >11.Patients currently taking nucleos(t)ide analogues/ immunosuppressive treatments within 30 days of study enrolment or systemic corticosteroids. <br/ >12.Presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation. <br/ >13.Patients having chronic bronchitis and/or emphysema, psychiatric, musculoskeletal, or cardiovascular diseases. <br/ >14.Patients suffering from concurrent systemic diseases, with cardiopulmonary tuberculosis, pulmonary eosinophilia, bronchiectasis, cancer, congestive heart failure, hepatic dysfunction, and neurological disorders. <br/ >15.Patients with severe disease, defined as pneumonia plus one of the following: respiratory rate â?¥30 per minute, breathlessness, SpO2 â?¤ 92 on room air. <br/ >16.Use of systemic corticosteroid therapy (this may affect peripheral muscle function). <br/ >17.Subjects who are known cases of immune-compromised or autoimmune condition such as HIV, Hepatitis. <br/ >18.ICU Patient and having severe COVID19 symptoms, known chronic kidney disease stage 4 or 5 or receiving dialysis. <br/ >19.Inability to take or tolerate oral medications.

N/A

N/A

1.Subjects who are not able to or not willing to sign an IRB/IEC approved consent form or refusal to participate by legally authorized representative, if present. <br/ >2.Hospitalization or need for immediate medical attention in the clinical opinion of the study investigator. <br/ >3.Haemoglobin <10 g/dL in men and <9 g/dL in women. <br/ > <br/ >4.Platelet count <125,000/L. <br/ > <br/ >5.Estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73m2 <br/ > <br/ >6.Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevated over 5 times the ULN. <br/ >7.Patient is Pregnant or lactating women <br/ > <br/ >8.Recipient of SARS-CoV-2 vaccine. <br/ > <br/ >9.Known allergy/sensitivity or any hypersensitivity to components of test drug, or its formulation. <br/ > <br/ >10.Use of therapeutic interventions with possible anti-SARS-CoV-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, convalescent plasma, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. <br/ >11.Patients currently taking nucleos(t)ide analogues/ immunosuppressive treatments within 30 days of study enrolment or systemic corticosteroids. <br/ >12.Presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation. <br/ >13.Patients having chronic bronchitis and/or emphysema, psychiatric, musculoskeletal, or cardiovascular diseases. <br/ >14.Patients suffering from concurrent systemic diseases, with cardiopulmonary tuberculosis, pulmonary eosinophilia, bronchiectasis, cancer, congestive heart failure, hepatic dysfunction, and neurological disorders. <br/ >15.Patients with severe disease, defined as pneumonia plus one of the following: respiratory rate â?¥30 per minute, breathlessness, SpO2 â?¤ 92 on room air. <br/ >16.Use of systemic corticosteroid therapy (this may affect peripheral muscle function). <br/ >17.Subjects who are known cases of immune-compromised or autoimmune condition such as HIV, Hepatitis. <br/ >18.ICU Patient and having severe COVID19 symptoms, known chronic kidney disease stage 4 or 5 or receiving dialysis. <br/ >19.Inability to take or tolerate oral medications.

1.Subjects who are not able to or not willing to sign an IRB/IEC approved consent form or refusal to participate by legally authorized representative, if present. <br/ >2.Hospitalization or need for immediate medical attention in the clinical opinion of the study investigator. <br/ >3.Haemoglobin <10 g/dL in men and <9 g/dL in women. <br/ > <br/ >4.Platelet count <125,000/L. <br/ > <br/ >5.Estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73m2 <br/ > <br/ >6.Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevated over 5 times the ULN. <br/ >7.Patient is Pregnant or lactating women <br/ > <br/ >8.Recipient of SARS-CoV-2 vaccine. <br/ > <br/ >9.Known allergy/sensitivity or any hypersensitivity to components of test drug, or its formulation. <br/ > <br/ >10.Use of therapeutic interventions with possible anti-SARS-CoV-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, convalescent plasma, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. <br/ >11.Patients currently taking nucleos(t)ide analogues/ immunosuppressive treatments within 30 days of study enrolment or systemic corticosteroids. <br/ >12.Presence of a condition, that in the opinion of the investigator, would place the subject at increased risk from study participation. <br/ >13.Patients having chronic bronchitis and/or emphysema, psychiatric, musculoskeletal, or cardiovascular diseases. <br/ >14.Patients suffering from concurrent systemic diseases, with cardiopulmonary tuberculosis, pulmonary eosinophilia, bronchiectasis, cancer, congestive heart failure, hepatic dysfunction, and neurological disorders. <br/ >15.Patients with severe disease, defined as pneumonia plus one of the following: respiratory rate â?¥30 per minute, breathlessness, SpO2 â?¤ 92 on room air. <br/ >16.Use of systemic corticosteroid therapy (this may affect peripheral muscle function). <br/ >17.Subjects who are known cases of immune-compromised or autoimmune condition such as HIV, Hepatitis. <br/ >18.ICU Patient and having severe COVID19 symptoms, known chronic kidney disease stage 4 or 5 or receiving dialysis. <br/ >19.Inability to take or tolerate oral medications.